Indeed, in the Translational Research Investigating Biomarker Endpoints in AKI (TRIBE AKI) study, the increase of these biomarkers, at the time of creatinine-based AKI diagnosis, was associated with an increased risk of AKI progression (urine IL-18 OR 3.0 (95% CI 1.3–7.3), albuminuria OR 3.4 (95% CI 1.3–9.1), and plasma NGAL OR 7.7 (95% CI 2.6–22.5)). The gene discussed is LCN2; the disease is acute kidney injury.